A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer

Sponsor

Amgen (Industry)

Overall Status

Withdrawn

CT.gov ID

NCT04466917

Collaborator

Parexel (Industry)

Enrollment

Arms

Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

The purpose of this research study is to assess the efficacy and safety of ABP 215 compared to Bevacizumab in Chinese patients with advanced non-small cell lung cancer (NSCLC).

Condition or Disease	Intervention/Treatment	Phase
Metastatic Non-small Cell Lung Cancer (NSCLC) Non-squamous NSCLC	Drug: ABP 215 Drug: Bevacizumab Drug: Paclitaxel Drug: Carboplatin	Phase 3

Detailed Description

Approximately 170 subjects will be randomized 1:1 in approximately 40 sites in China. This study consists of a screening period of up to 28 days, followed by a treatment period of 18 weeks, and an end of study visit 3 weeks after the last dose of investigational product or study-specified chemotherapy. After randomization, subjects will receive investigational product at a dose of 15 mg/kg administered every 3 weeks for 6 cycles followed by at least 4 and no more than 6 cycles of carboplatin and paclitaxel chemotherapy every 3 weeks.

Study Design

Study Type:

Interventional

Actual Enrollment :

0 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Intervention Model Description:

Subjects will be randomized to receive ABP 215 or bevacizumab on a 1:1 basis. All subjects will receive chemotherapy, following administration of investigational product.Subjects will be randomized to receive ABP 215 or bevacizumab on a 1:1 basis. All subjects will receive chemotherapy, following administration of investigational product.

Masking:

Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Masking Description:

Subjects, Amgen, designated PAREXEL, and other clinical site staff will be blinded to the investigational product allocation for each subject.

Primary Purpose:

Treatment

Official Title:

A Randomized, Double-blind, Phase 3 Bridging Study Evaluating the Safety and Efficacy of ABP 215 Compared With Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer

Anticipated Study Start Date :

May 15, 2021

Anticipated Primary Completion Date :

Nov 13, 2022

Anticipated Study Completion Date :

Nov 13, 2022

Arms and Interventions

Arm	Intervention/Treatment
Experimental: ABP 215 Subjects will be randomized to receive ABP 215 every 3 weeks (Q3W) for 6 cycles. All subjects will receive carboplatin and paclitaxel after the ABP 215 IV infusion every Q3W for at least 4 and not more than for 6 cycles.	Drug: ABP 215 ABP 215 will be administered at a dose of 15 mg/kg IV Drug: Paclitaxel Paclitaxel will be administered 175 mg/m2 IV Drug: Carboplatin Carboplatin will be administered at an area under the concentration-time curve (AUC) of 5 IV
Active Comparator: Bevacizumab Subjects will be randomized to receive Bevacizumab every 3 weeks (Q3W) for 6 cycles. All subjects will receive carboplatin and paclitaxel after the Bevacizumab IV infusion every Q3W for at least 4 and not more than for 6 cycles.	Drug: Bevacizumab Bevacizumab will be administered at a dose of 15 mg/kg IV Drug: Paclitaxel Paclitaxel will be administered 175 mg/m2 IV Drug: Carboplatin Carboplatin will be administered at an area under the concentration-time curve (AUC) of 5 IV

Arm

Intervention/Treatment

Experimental: ABP 215

Subjects will be randomized to receive ABP 215 every 3 weeks (Q3W) for 6 cycles. All subjects will receive carboplatin and paclitaxel after the ABP 215 IV infusion every Q3W for at least 4 and not more than for 6 cycles.

Drug: ABP 215

ABP 215 will be administered at a dose of 15 mg/kg IV

Drug: Paclitaxel

Paclitaxel will be administered 175 mg/m2 IV

Drug: Carboplatin

Carboplatin will be administered at an area under the concentration-time curve (AUC) of 5 IV

Active Comparator: Bevacizumab

Subjects will be randomized to receive Bevacizumab every 3 weeks (Q3W) for 6 cycles. All subjects will receive carboplatin and paclitaxel after the Bevacizumab IV infusion every Q3W for at least 4 and not more than for 6 cycles.

Drug: Bevacizumab

Bevacizumab will be administered at a dose of 15 mg/kg IV

Drug: Paclitaxel

Paclitaxel will be administered 175 mg/m2 IV

Drug: Carboplatin

Carboplatin will be administered at an area under the concentration-time curve (AUC) of 5 IV

Outcome Measures

Primary Outcome Measures

Objective response rate (ORR) [From Day 1 to Week 19 (EOS)]
The percentage of subjects with a best overall tumor response of Complete Response (CR) or Partial Response (PR).

Secondary Outcome Measures

Progression-free survival (PFS) [From Day 1 to Week 19 (EOS)]
Duration of response (DOR) [From Day 1 to Week 19 (EOS)]
Maximum Plasma Concentration (Cmax) [Pre-dose on Week 1, Week 4, Week 7, Week 13 and Week 19 (EOS)]
Area Under the Curve (AUC) [Pre-dose on Week 1, Week 4, Week 7, Week 13 and Week 19 (EOS)]
Minimum observed concentration (Cmin) [Pre-dose on Week 1, Week 4, Week 7, Week 13 and Week 19 (EOS)]
Number of participants with treatment-emergent adverse events [From Screening to Week 19 (EOS)]
Number of participants with treatment-emergent events of interest (EOIs) [From Screening to Week 19 (EOS)]
Number of participants with incidence of anti-drug antibodies (ADAs) [On Week 1, Week 7, Week 13 and Week 19 (EOS)]

Eligibility Criteria

Criteria

Ages Eligible for Study:

N/A and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Histologically or cytologically confirmed non-squamous NSCLC.
Subjects must be initiating first-line carboplatin/paclitaxel chemotherapy within 8 days after randomization and expected to receive at least 4 and no more than 6 cycles of chemotherapy.
Eastern Cooperative Oncology Group (ECOG) performance status score 0 or 1.
Other inclusion criteria may apply.

Exclusion Criteria:

Small cell lung cancer (SCLC) or mixed SCLC and NSCLC.
Central nervous system (CNS) metastases.
Malignancy other than NSCLC.
Palliative radiotherapy for bone lesions inside the thorax.
Prior radiotherapy of bone marrow.
Active hepatitis B.
Active hepatitis C.
Tested positive for human immunodeficiency virus (HIV).
Life expectancy < 6 months.
Woman of childbearing potential who is pregnant or is breast feeding.
Woman of childbearing potential who is not consenting to use highly effective methods of birth control during treatment and for an additional 6 months after the last administration of the protocol specified treatment.
Man with a partner of childbearing potential who does not consent to use highly effective methods of birth control during treatment and for an additional 6 months after the last administration of the protocol specified treatment.
Other exclusion criteria may apply.